DexCom Inc (DXCM)vsWells Fargo & Company (WFC)
DXCM
DexCom Inc
$73.74
+1.94%
HEALTHCARE · Cap: $28.45B
WFC
Wells Fargo & Company
$77.54
-0.96%
FINANCIAL SERVICES · Cap: $225.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Wells Fargo & Company generates 1584% more annual revenue ($81.14B vs $4.82B). WFC leads profitability with a 26.7% profit margin vs 19.3%. WFC appears more attractively valued with a PEG of 1.34. WFC earns a higher WallStSmart Score of 74/100 (B).
DXCM
Strong Buy72
out of 100
Grade: B
WFC
Strong Buy74
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+89.8%
Fair Value
$669.08
Current Price
$73.74
$595.34 discount
Intrinsic value data unavailable for WFC.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 31 in profit
Earnings expanding 92.2% YoY
Strong operational efficiency at 21.4%
15.0% revenue growth
Mega-cap, among the largest globally
Attractively priced relative to earnings
Reasonable price relative to book value
Keeps 27 of every $100 in revenue as profit
Strong operational efficiency at 29.4%
Generating 9.1B in free cash flow
Areas to Watch
Premium valuation, high expectations priced in
Trading at 9.6x book value
Distress zone — elevated risk
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : DXCM
The strongest argument for DXCM centers on Return on Equity, EPS Growth, Operating Margin. Profitability is solid with margins at 19.3% and operating margin at 21.4%. Revenue growth of 15.0% demonstrates continued momentum.
Bull Case : WFC
The strongest argument for WFC centers on Market Cap, P/E Ratio, Price/Book. Profitability is solid with margins at 26.7% and operating margin at 29.4%. PEG of 1.34 suggests the stock is reasonably priced for its growth.
Bear Case : DXCM
The primary concerns for DXCM are P/E Ratio, Price/Book.
Bear Case : WFC
The primary concerns for WFC are Altman Z-Score, Debt/Equity. Debt-to-equity of 2.53 is elevated, increasing financial risk.
Key Dynamics to Monitor
DXCM carries more volatility with a beta of 1.40 — expect wider price swings.
DXCM is growing revenue faster at 15.0% — sustainability is the question.
WFC generates stronger free cash flow (9.1B), providing more financial flexibility.
Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
WFC scores higher overall (74/100 vs 72/100), backed by strong 26.7% margins. DXCM offers better value entry with a 89.8% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
DexCom Inc
HEALTHCARE · MEDICAL DEVICES · USA
DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.
Wells Fargo & Company
FINANCIAL SERVICES · BANKS - DIVERSIFIED · USA
Wells Fargo & Company is an American multinational financial services company with corporate headquarters in San Francisco, California, operational headquarters in Manhattan, and managerial offices throughout the United States and overseas.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?